{"id":20953,"date":"2025-01-08T16:21:42","date_gmt":"2025-01-08T08:21:42","guid":{"rendered":"https:\/\/flcube.com\/?p=20953"},"modified":"2025-01-08T16:21:43","modified_gmt":"2025-01-08T08:21:43","slug":"boehringer-ingelheim-and-sutro-achieve-commercial-scale-manufacturing-of-luvelta","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20953","title":{"rendered":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta"},"content":{"rendered":"\n<p>Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.<\/p>\n\n\n\n<p><strong>Product Profile and Technology<\/strong><br>Luvelta is Sutro\u2019s Tubulin FR\u03b1-targeting antibody-drug conjugate (ADC), designed to treat a broad range of patients with ovarian cancer and other FR\u03b1-expressing cancers. The partial synthesis process of STRO-002\u2019s FR alpha-targeted antibody is realized by the industry-leading cell-free protein synthesis technology (XpressCF), which can embed non-natural amino acids (XpressCF+) at specific protein sites. The non-natural amino acid side chains of the obtained antibody can be introduced into the cleavable linker small molecule load through a click chemistry reaction site, achieving ADC site-specific coupling.<\/p>\n\n\n\n<p><strong>Advantages and Applications<\/strong><br>The DAR value (drug antibody ratio) of STRO-002 is 4, indicating high product uniformity, which is expected to solve the problems of pharmaceutical quality and pharmacology caused by traditional ADC non-site coupling. Additionally, the small molecule load of STRO-002 is a derivative of the marine extract Hamitrin, a novel microtubule inhibitor and weak substrate for P-glycoprotein pumps, with the potential to address drug resistance.<\/p>\n\n\n\n<p><strong>Significance of the Achievement<\/strong><br>This milestone underscores the effectiveness of Sutro\u2019s cell-free protein synthesis technology in scaling up production while maintaining high product quality. The collaboration with Boehringer Ingelheim highlights the potential of this technology to revolutionize the manufacturing process for complex biologics, ensuring more efficient and consistent production for clinical and commercial needs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":20957,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,3084,390,2310],"class_list":["post-20953","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-bioxcellence","tag-boehringer-ingelheim","tag-sutro-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20953\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20953\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T08:21:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T08:21:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta\",\"datePublished\":\"2025-01-08T08:21:42+00:00\",\"dateModified\":\"2025-01-08T08:21:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0810.png\",\"keywords\":[\"ADC \\\/ XDC\",\"BioXcellence\",\"Boehringer Ingelheim\",\"Sutro Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20953#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20953\",\"name\":\"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0810.png\",\"datePublished\":\"2025-01-08T08:21:42+00:00\",\"dateModified\":\"2025-01-08T08:21:43+00:00\",\"description\":\"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20953\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0810.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0810.png\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20953#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20953","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta","og_description":"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.","og_url":"https:\/\/flcube.com\/?p=20953","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T08:21:42+00:00","article_modified_time":"2025-01-08T08:21:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20953#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20953"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta","datePublished":"2025-01-08T08:21:42+00:00","dateModified":"2025-01-08T08:21:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20953"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20953#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","keywords":["ADC \/ XDC","BioXcellence","Boehringer Ingelheim","Sutro Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20953#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20953","url":"https:\/\/flcube.com\/?p=20953","name":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20953#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20953#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","datePublished":"2025-01-08T08:21:42+00:00","dateModified":"2025-01-08T08:21:43+00:00","description":"Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro\u2019s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta). This marks the first time Sutro\u2019s cell-free protein synthesis platform has scaled from small-scale Good Manufacturing Practice (GMP) production to large-scale GMP production. All batches of luvelta manufactured in 4,500 L at Boehringer\u2019s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for use in clinical studies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20953#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20953"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20953#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","width":1080,"height":608,"caption":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20953#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0810.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20953"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20953\/revisions"}],"predecessor-version":[{"id":20958,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20953\/revisions\/20958"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20957"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}